Author Correction: Egyptian metallic inks on textiles from the 15th century BCE unravelled by non-invasive techniques and chemometric analysis.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Egyptian metallic inks on textiles from the 15th century BCE unravelled by non-invasive techniques and chemometric analysis.

The development of black inks has enabled writing to become an established method of communication in history. Although a large research effort has been devoted to the study of pigments and dyes used in ancient Egypt to decorate burial walls and furnishings, or to write on papyrus, to date little attention has been paid to the nature and technology of inks used on ritual and daily-use textiles, which may have fostered the transfer of metallic ink technology onto papyrus and parchment supports. We report about inks from 15th century BCE Egyptian textiles by combining non-invasive techniques, including ultraviolet (UV) reflected imaging, near-infrared reflectography (NIRR), X-ray fluorescence (XRF) spectroscopy, Raman spectroscopy and prompt-gamma-activation-analysis (PGAA). It is argued that the inks are related to the family of iron gall inks, whose introduction is commonly attributed to the third century BCE. This interpretation frames the technology of writing on fabrics, used by the ancient Egyptians, in a different time, thus providing new information on the genesis of mordant inks in the ancient Mediterranean cultures. We anticipate our study to be a starting point for further and more sophisticated investigations of textiles, which will clarify the origin of metallic ink in the ancient world.

The understanding of the emotional meaning of facial expressions in people with autism.

Ten autistic individuals (mean age: 12.7 years, SD 3.8, range 5.10-16.0), 10 Down individuals (12.3 years, SD 3.0, range 7.1-16.0), and a control group of 10 children with normal development (mean age: 6.3 years, SD 1.6, range 4.0-9.4), matched for verbal mental age, were tested on a delayed-matching task and on a sorting-by-preference task. The first task required subjects to match faces on the basis of the emotion being expressed or on the basis of identity. Different from the typical simultaneous matching procedure the target picture was shortly presented (750 msec) and was not visible when the sample pictures were shown to the subject, thus reducing the possible use of perceptual, piecemeal, processing strategies based on the typical features of the emotional facial expression. In the second task, subjects were required to rate the valence of an isolated stimulus, such as facial expression of emotion or an emotional situation in which no people were represented. The aim of the second task was to compare the autistic and nonautistic children's tendency to judge pleasantness of a face using facial expression of emotion as a meaningful index. Results showed a significantly worse performance in autistic individuals than in both normal and Down subjects on both facial expression of emotion subtasks, although on the identity and emotional situation subtasks there were no significant differences between groups.

Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model.

Next generation vaccine adjuvants include Toll like receptor agonists, which are mostly extracted from microorganisms, but synthetic small molecule TLR agonists have also been identified. However, their delivery systems have not been optimized for effective administration in conjunction with antigens. Here, we describe a novel approach in which a small molecule TLR agonist was directly conjugated to antigen to ensure effective co-delivery. We describe the conjugation of a recombinant protective antigen from Streptococcus pneumoniae linked to a TLR7 agonist. Following thorough characterization to ensure no aggregation, the conjugate was evaluated in a murine infection model. Results showed that the conjugate extended the animals' survival after lethal challenge with S. pneumoniae. Comparable results were obtained with a dose 10-fold lower than that of the native unconjugated antigen. Notably, the animals immunized with the same dose of unconjugated TLR7 agonist and antigen showed no adjuvant effect. The increased immunogenicity was likely a consequence of the co-localization of TLR7 agonist and antigen by chemical binding and was more effective than simple co-administration. This approach can be adopted to increase potency of a broad variety of antigens and reduce the dose of antigen required to induce protective immunity.